With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the 'Company'), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387 is well-positioned to support preparedness efforts and to combat potential pandemics.
Nimbus, a new COVID variant, officially NB1.8.1, is displacing the LP8.1 variant that was dominant until a few weeks ago in the USA ( https://www.today.com/health/coronavirus/new-covid-variant-nb181-nimbus-symptoms-rcna212304 ).
Nimbus has been rising globally since Spring according to WHO ( https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf ).
Nimbus causes 'razor-sharp' sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms.
Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC.
Nimbus is likely to be more transmissible than the previous variants. It belongs to the JN.1 subfamily of the Omicron family of SARS-CoV-2 virus.
Recently, the Influenza A H5N1 virus from a dairy worker in Michigan was found to be capable of airborne transmission in a ferret animal model [1] ( https://www.freep.com/story/news/health/2025/06/05/h5n1-bird-flu-michigan-dairy-farm-airborne-spread-cdc-study/84046550007/ ). This genotype B3.13 (clade clade 2.3.4.4b) virus in dairy cattle causes moderate severity disease in humans. In contrast, a highly pathogenic genotype D1.1 that is circulating in birds birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans.
Additionally, a new genotype of H5N1 in Cambodia has caused four fatalities and fifth severe infection as of today ( https://www.cidrap.umn.edu/avian-influenza-bird-flu/h5n1-avian-flu-infects-fifth-patient-cambodia ).
NV-387, the broad-spectrum antiviral drug is expected to be effective against all of these bird flu viruses. NV-387 was found to be substantially superior to Tamiflu® (Roche, Oseltamivir), Rapivab® (Biocryst, Peramivir), as well as Xofluza (Shionogi/Roche, baloxavir) in lethal lung infection animal model of Influenza infection. All three of these existing anti-influenza drugs are known to be escaped by Influenza viruses by single point mutations in H or PB2 genes.
NV-387 was found to be substantially superior to the approved drug Remdesivir in a lethal coronavirus lung infection animal model for SARS-CoV-2.
Thus the single drug NV-387 alone can combat H5N1, Influenza as well as COVID infections.
NV-387 has completed Phase I clinical trial in healthy human subjects with no reported adverse events.
COVID as well as Influenza viruses readily escape vaccines, antibodies as they change in the field during an epidemic wave. They are also likely to escape small molecule drugs by such changes.
NV-387 takes advantage of the invariant features that these viruses use for causing infection, by mimicking heparan sulfate-like structures. No matter how much these viruses change in the field, they continue to use the heparan sulfate attachment receptors in order to cause infection. Thus it is practically impossible that the viruses may be able escape NV-387 without losing their ability infect and transmit across humans, the Company believes.
NV-387 is orally available, formulated as oral gummies that dissolve in the mouth, thus avoiding issues of inability to swallow which occurs related to sore throat, old age, as well as in young children.
NV-387, as a treatment, is designed to help actually patients with disease recover rapidly, thus limiting the viral spread as well as providing for natural infection-based immunity in the recovered patient.
'NV-387 is thus the best current choice available for a highly cost-effective pandemic preparedness development,' said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, 'We have US-based cGMP manufacturing capabilities already set up as well.'
Of note, natural immunity, as induced by recovery from infection, is known to be superior to immunity from subunit and mRNA vaccines. One of the important reasons is that in natural infection, the immune system is subjected to all possible antigens from the entire virus, unlike just the selected antigens or antigen fragments that are present in subunit or mRNA vaccines.
Also, NV-387 can be manufactured in the USA and stockpiled readily at room temperature or refrigeration (for longer periods of time).
Unlike NV-387, vaccines or antibodies would require to be created after the virus takes hold, and they would suffer substantial loss of effectiveness within months after deployment due to changes in the virus. Additionally, vaccines require a cold chain handling. Vaccines also need to be administered to a large proportion of healthy population. There are significant logistical problems with vaccines. There is also the issue of vaccine reluctance, which is a personal choice, as it should be in a free country like the USA.
The broad-spectrum antiviral drug NV-387 was developed specifically to overcome all of these problems. In case of further spread of a severe COVID variant and also a Bird Flu variant in human populations, it will be possible to move NV-387 rapidly into Phase II clinical trial for these diseases, and then prepare for deployment early in the potential pandemic, curtailing its spread.
About NanoViricides
NanoViricides, Inc. (the 'Company') ( www.nanoviricides.com ) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
[email protected]
Public Relations Contact:
[email protected]
Brock N, Pulit-Penaloza JA, Belser JA, et al. Avian Influenza A(H5N1) Isolated from Dairy Farm Worker, Michigan, USA. Emerging Infectious Diseases. 2025;31(6):1253-1256. doi:10.3201/eid3106.250386.
SOURCE: NanoViricides, Inc.
press release

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

22 minutes ago

• Bloomberg

How Robotic Hives and AI Are Lowering the Risk of Bee Colony Collapse

Green Cleaner Tech After 150 years without minimal innovation, the beehive is getting an upgrade that is making it easier to protect colonies and the crops that rely on them. By Lifting up the hood of a Beewise hive feels more like you're getting ready to examine the engine of a car than visit with a few thousand pollinators. The unit — dubbed a BeeHome — is an industrial upgrade from the standard wooden beehives, all clad in white metal and solar panels. Inside sits a high-tech scanner and robotic arm powered by artificial intelligence. Roughly 300,000 of these units are in use across the US, scattered across fields of almond, canola, pistachios and other crops that require pollination to grow.

USA Today

30 minutes ago

• USA Today

RFK Jr. dismissing experts creates deadly vaccine hesitancy

Kennedy has long planted the seeds of vaccine hesitancy, despite evidence that contradicts his falsehoods. Now we are once again seeing more children succumb to vaccine-preventable diseases. Since 1964, pediatricians have looked to the Advisory Committee on Immunization Practices to provide evidence-based recommendations regarding childhood vaccines. We represent more than 80 years of experience as pediatricians in Nashville and have benefitted from ACIP throughout our careers. On June 9, our clinic days were disrupted by the news that Health and Human Services Secretary Robert F. Kennedy Jr. had dismissed all 17 ACIP members. These members are academic clinicians, epidemiologists, immunologists and infectious disease experts. Their service was driven not by money or fame, but by a commitment to the collective health of Americans. ACIP meetings were transparent, being broadcast live and then archived on YouTube, while agendas were posted well in advance of each meeting. The public could request to ask questions at meetings as well as review slide decks that were presented. ACIP worked to avoid member conflicts of interest Kennedy's implication that he was reconstructing the committee to prevent conflicts of interest is far from the truth. In order to preserve objectivity and limit corporate influence on their recommendations, ACIP members already disclose any potential conflict of interest in advance. If a member has a potential conflict, they are not permitted to participate in vaccine discussions, or to vote on that vaccine or any vaccine that a company might bring before ACIP – even if that member didn't work on that specific vaccine. Opinion: As a doctor, I know it will take more than dietary changes to Make America Healthy Again Kennedy also implied that ACIP only ever adds vaccines to the schedule, acting as a rubber stamp for industry. But ACIP recommendations came after analyzing evidence and weighing the benefits and risks. The 1972 decision to stop vaccinating for smallpox was a significant and very well-informed move, reflecting an in-depth understanding of both the science and the broader public health context. The 2016 recommendation to reduce the number of doses for the HPV vaccine also shows that ACIP actively engaged in fine-tuning vaccination schedules based on the latest research, rather than to increase industry profits. It's crucial for these bodies to make decisions based on science, not external pressures or adherence to a certain ideology. Kennedy creates vaccine hesitancy that lead to childhood diseases As pediatricians, we have seen patients die from vaccine-preventable diseases. Our pediatric forefathers cared for children in iron lungs due to paralytic polio. Opinion: Please stop letting RFK Jr. make vaccine policies. His new COVID plan is deadly. Kennedy has planted the seeds of the anti-vaccination movement for more than two decades, despite evidence that contradicts his falsehoods. Due to the vaccine hesitancy and refusal he promotes, we are once again seeing more children succumb to vaccine-preventable diseases in America. So far in 2025, we have had pediatric deaths from measles and whooping cough, not to mention more than 200 deaths from influenza. Those numbers will only escalate in the future. Kennedy's decision to eliminate trustworthy members of the ACIP fundamentally changes the nature of this committee. Institutional memory and the trust of physicians were obliterated in one fell swoop. We hold little hope that HHS can put a new trusted committee together in time for the next scheduled ACIP meeting Jun 25-26, given Kennedy's preference for conspiracy theorists and other unqualified people. Through our careers as community pediatricians, we have been blessed by the opportunity to partner with wonderful families who desire what is best for their children. We fervently hope this relationship will be the most important factor when families make decisions regarding vaccinating their children. We call on our elected officials to reinstate the ACIP members Kennedy dismissed and to empower them to continue their work to limit damage from infectious diseases. Doing so will actually help make Americans healthier. James Keffer, MD; Chetan R Mukundan, MD; Jill Obremsky, MD; Elizabeth Triggs, MD; and David Wyckoff, MD, are local pediatricians practicing in different settings around Nashville. This column originally appeared in The Tennessean.

Forbes

34 minutes ago

• Forbes

Sync Your Summer With The Stars With This Sky Calendar Until Labor Day

Summer nights will bring everything from planets, full moons, and star-studded constellations to ... More "shooting stars," the Milky Way, and more. Summer is the season for stargazing. Sure, nights can be short if you're in northerly latitudes, but the warm evenings — and the higher chance of people being outside, camping and barbecuing — make late June, July and August prime time for sky-watching. From yesterday's solstice through Labor Day on September 1, nightfall brings everything from planets, full moons, and star-studded constellations to "shooting stars," the Milky Way, and more. Here's everything you need to know about the night sky this summer 2025. 1. Crescent Moon And Venus Beside The Pleiades Where: east When: an hour before sunrise where you are on Sunday, Jun. 22 A beautiful trio in the dawn twilight is the reward for anyone dedicated enough to get up before sunrise, with the 13%-lit crescent moon above brilliant Venus with the delicate stars of the Pleiades to the left. Sunday, June 22: Venus, A Crescent Moon And The Pleiades 2. See The Full 'Buck Moon' Rise Where: east When: moonrise where you are during dusk on Thursday, Jul. 10 The first full moon of summer will rise dramatically in the eastern sky just after sunset. Known as the Buck Moon, it will stay low in the southern sky all night and, as a consequence, appear to be especially large. 3. The Milky Way At Its Best Where: southeast When: after dark from July 17-27 and August 16-26 Just after dark, bright star Altair — the southernmost point of the Summer Triangle — shines brightly in the southeast. Get away from light pollution and look around and below it during either 10-night dark-sky window (when the moon is down), and you'll get eyes-on with the Milky Way running beneath. CHIFENG, CHINA - AUGUST 14, 2023 - The Perseid meteor shower is seen over the Ulanbum grassland in ... More Chifeng city, Inner Mongolia, China, August 14, 2023. (Photo by Costfoto/NurPhoto via Getty Images) 4. Perseids Meteor Shower Where: All-sky When: Thursday, Jul. 17- Friday, Aug. 15 The annual Perseid meteor shower kicks off on Jul. 15, building toward its famous peak on August 12/13. Sadly, that night will feature a bright sky bleached by a nearly full moon. So start looking early — you may see a few bright meteors streak across the post-sunset sky around midnight. 5. See The Full 'Sturgeon Moon' Rise Where: east When: moonrise where you are during dusk on Friday, Aug. 8 and Saturday, Aug. 9 If you have a choice, find an east-facing beach for your summer vacation to watch August's full Sturgeon Moon rise shortly after the sun sets, glowing a deep orange as it climbs the eastern horizon. Celestial mechanics means it rises just after sunset on two successive nights this month. The summer triangle stars chart in the Northern Hemisphere 6. The Summer Triangle Where: southeast When: after dark, anytime in August The brilliant stars Vega and Deneb are high overhead after dark, the top of the iconic Summer Triangle, with Altair below completing the elongated shape. It's one of the easiest shapes of stars to spot — and it also marks the arc of the Milky Way flowing down to the southern horizon during August. 7. Jupiter And Venus In Conjunction Where: east-northeast When: an hour before sunrise where you are on Tuesday, Aug. 12 Less than a degree — the width of an outstretched little finger held against the sky — will separate Jupiter and Venus this morning in a rare close conjunction. Uranus, Neptune and Saturn will also be in the sky, though the former two are impossible to see with the naked eye and the latter difficult. Wednesday, August 20: 'Planet Parade' And A Moon-Venus Conjunction 8. 'Planet Parade' At Dawn Where: west When: an hour before sunrise where you are on Monday, Aug. 18 through Thursday, Aug. 21 Mercury, Venus, Mars, and Saturn will be visible in the same sky in 2025's second "planet parade." As a bonus, a waning crescent moon will slip between the planets across four mornings, with a conjunction with Venus on Wednesday, Aug. 20. Wishing you clear skies and wide eyes.